Thorsélius Mia, Kröber Alexander, Murray Fiona, Thunberg Ulf, Tobin Gerard, Bühler Andreas, Kienle Dirk, Albesiano Emilia, Maffei Rossana, Dao-Ung Lan-Phuong, Wiley James, Vilpo Juhani, Laurell Anna, Merup Mats, Roos Göran, Karlsson Karin, Chiorazzi Nicholas, Marasca Roberto, Döhner Hartmut, Stilgenbauer Stephan, Rosenquist Richard
Department of Genetic and Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden.
Blood. 2006 Apr 1;107(7):2889-94. doi: 10.1182/blood-2005-06-2227. Epub 2005 Nov 29.
We recently reported that Swedish VH3-21-using chronic lymphocytic leukemia (CLL) patients showed restricted immunoglobulin gene features and poor prognosis despite VH mutation status. To investigate this further, we analyzed the VH and VL gene rearrangements in 90 VH3-21+ patients from Sweden, Germany, Italy, United States, Finland, and Australia and correlated these data with survival and other prognostic markers. Sixty-three percent exhibited mutated VH genes and 37% unmutated VH genes. Fifty (56%) patients displayed a short and homologous heavy-chain CDR3, many of these with the amino acid motif DANGMDV. Also, a highly biased Vlambda2-14 use was evident in 72% of patients with a restricted light-chain CDR3, QVWDS(S/G)SDHPWV. Combined restricted heavy- and light-chain CDR3s were found in patients from all included countries. Although VH3-21+ CLLs have a remarkably predominant lambda expression, analyses of kappa deleting element indicated a conserved light-chain rearrangement order. The overall survival was poor in the VH3-21+ cohort (median survival, 88 months), with no significant difference in relation to mutation status or CDR3 homology. High ZAP-70 and CD38 expression was found in both mutated and unmutated VH3-21+ cases as well as a slight increase of 11q-aberrations. In summary, highly restricted B-cell receptors and worse outcome characterize VH3-21+ CLLs independent of geographic origin and mutation status.
我们最近报告称,使用VH3-21的瑞典慢性淋巴细胞白血病(CLL)患者尽管存在VH突变状态,但仍表现出受限的免疫球蛋白基因特征和不良预后。为了进一步研究这一情况,我们分析了来自瑞典、德国、意大利、美国、芬兰和澳大利亚的90例VH3-21+患者的VH和VL基因重排,并将这些数据与生存情况及其他预后标志物相关联。63%的患者VH基因发生突变,37%的患者VH基因未发生突变。50例(56%)患者的重链CDR3短且具有同源性,其中许多具有氨基酸基序DANGMDV。此外,在72%轻链CDR3受限(QVWDS(S/G)SDHPWV)的患者中,Vlambda2-14的使用明显偏向。在所有纳入国家的患者中均发现了重链和轻链CDR3均受限的情况。尽管VH3-21+ CLLs具有明显占主导的lambda表达,但κ缺失元件分析表明轻链重排顺序保守。VH3-21+队列的总生存期较差(中位生存期为88个月),在突变状态或CDR3同源性方面无显著差异。在VH3-21+突变和未突变病例中均发现高ZAP-70和CD38表达,以及11q畸变略有增加。总之,高度受限的B细胞受体和较差的预后是VH3-21+ CLLs的特征,与地理来源和突变状态无关。